Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study.
5-aminosalicylic acid
activity
inflammatory indexes
severity
ulcerative colitis
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
01
2022
accepted:
07
02
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Active and severe ulcerative colitis (UC) and non-response to 5-aminosalicylic acid (5-ASA) are related to poor outcomes and should be accurately identified. Several integrated inflammatory indexes are potentially useful to assess the disease severity in patients with acute or critical diseases but are underexplored in patients with UC. Patients with UC consecutively admitted to our hospital between January 2015 and December 2020 were retrospectively grouped according to the activity and severity of UC and response to 5-ASA. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), neutrophil-to-platelet ratio (NPR), platelet-to-albumin ratio (PAR), C-reactive protein-to-albumin ratio (CAR), and C-reactive protein-to-lymphocyte ratio (CLR) were calculated. The areas under receiver operating characteristic curves (AUC) were calculated. Overall, 187 patients with UC were included, of whom 151 were active, 55 were severe, and 14 were unresponsive to 5-ASA. The active UC group had significantly higher NLR, PLR, SII, and PAR levels. SII had the greatest predictive accuracy for active UC, followed by PLR, PAR, and NLR (AUC = 0.647, 0.641, 0.634, and 0.626). The severe UC group had significantly higher NLR, PLR, SII, PAR, CAR, and CLR levels. CLR had the greatest predictive accuracy for severe UC, followed by CAR, PLR, SII, NLR, and PAR (AUC = 0.732, 0.714, 0.693, 0.669, 0.646, and 0.63). The non-response to the 5-ASA group had significantly higher CAR and CLR levels. CAR had a greater predictive accuracy for non-response to 5-ASA than CLR (AUC = 0.781 and 0.759). SII, CLR, and CAR may be useful for assessing the severity and progression of UC, but remain not optimal.
Sections du résumé
Background
Active and severe ulcerative colitis (UC) and non-response to 5-aminosalicylic acid (5-ASA) are related to poor outcomes and should be accurately identified. Several integrated inflammatory indexes are potentially useful to assess the disease severity in patients with acute or critical diseases but are underexplored in patients with UC.
Methods
Patients with UC consecutively admitted to our hospital between January 2015 and December 2020 were retrospectively grouped according to the activity and severity of UC and response to 5-ASA. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), neutrophil-to-platelet ratio (NPR), platelet-to-albumin ratio (PAR), C-reactive protein-to-albumin ratio (CAR), and C-reactive protein-to-lymphocyte ratio (CLR) were calculated. The areas under receiver operating characteristic curves (AUC) were calculated.
Results
Overall, 187 patients with UC were included, of whom 151 were active, 55 were severe, and 14 were unresponsive to 5-ASA. The active UC group had significantly higher NLR, PLR, SII, and PAR levels. SII had the greatest predictive accuracy for active UC, followed by PLR, PAR, and NLR (AUC = 0.647, 0.641, 0.634, and 0.626). The severe UC group had significantly higher NLR, PLR, SII, PAR, CAR, and CLR levels. CLR had the greatest predictive accuracy for severe UC, followed by CAR, PLR, SII, NLR, and PAR (AUC = 0.732, 0.714, 0.693, 0.669, 0.646, and 0.63). The non-response to the 5-ASA group had significantly higher CAR and CLR levels. CAR had a greater predictive accuracy for non-response to 5-ASA than CLR (AUC = 0.781 and 0.759).
Conclusion
SII, CLR, and CAR may be useful for assessing the severity and progression of UC, but remain not optimal.
Identifiants
pubmed: 35359771
doi: 10.3389/fpubh.2022.851295
pmc: PMC8963422
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
851295Informations de copyright
Copyright © 2022 Lin, Bai, Wu, Chu, Zhang, Guo and Qi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Dig Dis Sci. 2011 Jun;56(6):1801-5
pubmed: 21127977
Clin Med (Lond). 2009 Feb;9(1):30-3
pubmed: 19271597
Gut Liver. 2016 Jul 15;10(4):595-603
pubmed: 27021506
J Neuroimmunol. 2012 May 15;246(1-2):1-9
pubmed: 22445294
Am J Gastroenterol. 2001 Mar;96(3):776-81
pubmed: 11280550
Clin Chem Lab Med. 2017 May 1;55(6):899-906
pubmed: 27987356
J Clin Biochem Nutr. 2019 May;64(3):265-270
pubmed: 31138962
Eur J Clin Invest. 1994 Feb;24 Suppl 1:16-20
pubmed: 8013527
Inflamm Bowel Dis. 2016 Dec;22(12):2956-2965
pubmed: 27763951
Gut. 2006 Mar;55(3):426-31
pubmed: 16474109
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
J Crohns Colitis. 2015 Oct;9(10):837-45
pubmed: 26188352
Aliment Pharmacol Ther. 2020 Dec;52(11-12):1658-1675
pubmed: 33086438
Gut. 2006 Jun;55(6):749-53
pubmed: 16698746
Nat Immunol. 2008 Dec;9(12):1341-6
pubmed: 18931678
Aliment Pharmacol Ther. 2016 Jan;43(2):252-61
pubmed: 26549003
Immunity. 2010 Nov 24;33(5):657-70
pubmed: 21094463
Clin Gastroenterol Hepatol. 2013 Jan;11(1):49-54.e1
pubmed: 22902762
J Interferon Cytokine Res. 1999 Jul;19(7):757-60
pubmed: 10454346
Gastroenterology. 2019 Feb;156(3):748-764
pubmed: 30576644
Anticancer Res. 2017 Feb;37(2):787-793
pubmed: 28179331
Aliment Pharmacol Ther. 2020 Jun;51(11):1039-1046
pubmed: 32291786
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Dig Dis. 2012;30(4):368-75
pubmed: 22796798
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
J Clin Invest. 2010 Jul;120(7):2423-31
pubmed: 20516641
Nat Immunol. 2008 Dec;9(12):1347-55
pubmed: 18997793
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
J Crohns Colitis. 2021 Jul 5;15(7):1120-1129
pubmed: 33438008
Inflamm Bowel Dis. 2013 Mar-Apr;19(4):720-8
pubmed: 23429464
J Mol Model. 2008 Dec;14(12):1111-7
pubmed: 18682993
Clin Gastroenterol Hepatol. 2016 Jun;14(6):829-835.e1
pubmed: 26820402
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
Surgery. 2008 May;143(5):658-66
pubmed: 18436014
Eur J Pharm Biopharm. 2018 Apr;125:141-147
pubmed: 29407223
J Clin Gastroenterol. 2018 Jul;52(6):e48-e52
pubmed: 28737646
Am J Gastroenterol. 2004 May;99(5):938-45
pubmed: 15128364
J Dig Dis. 2008 Nov;9(4):219-24
pubmed: 18959594
Gastroenterol Clin North Am. 2020 Dec;49(4):671-688
pubmed: 33121688
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Ther Apher Dial. 2003 Feb;7(1):48-59
pubmed: 12921115
Clin Chim Acta. 2021 Jun;517:122-126
pubmed: 33662359
Inflamm Bowel Dis. 2013 Mar-Apr;19(4):779-84
pubmed: 23446338
Aliment Pharmacol Ther. 2013 Oct;38(8):935-45
pubmed: 24004000
Immunity. 2003 Oct;19(4):583-93
pubmed: 14563322
Nat Rev Dis Primers. 2020 Sep 10;6(1):74
pubmed: 32913180
Gastroenterology. 2019 Apr;156(5):1345-1353.e4
pubmed: 30639677
Gastroenterol Res Pract. 2020 Jun 22;2020:3467419
pubmed: 32655630
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Gut. 2007 May;56(5):725-32
pubmed: 17440187
Dig Dis Sci. 2018 Feb;63(2):277-288
pubmed: 29275447
Br Med J. 1955 Oct 29;2(4947):1041-8
pubmed: 13260656
Intest Res. 2022 Jan;20(1):101-113
pubmed: 33902267
Dig Surg. 2020;37(6):515-523
pubmed: 33105139
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132